15 September 2021 - NICE has recommended Bristol Myers Squibb’s (BMS) immunotherapy Opdivo (nivolumab) for routine use on the NHS as a treatment for metastatic and recurrent head and neck cancer.

In January, NICE published draft guidance in which it turned down Opdivo for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy.

Read Pharma Times article